Granted Patent
B2
US 12,195,728 · App. 18/742,215 · Granted Jan 14, 2025
Method for making pluripotent stem cells
Assignee:
MINERVA BIOTECHNOLOGIES CORPORATION
C12N11/06A61K31/7088C07K16/2863C07K16/3092C12N5/0606C12N5/0696C12Q1/6881C07K2317/35C07K2317/75C12N2500/98C12N2501/115C12N2501/727C12N2533/50C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application discloses a method for inducing cells to gain characteristics of naïve stem cell state comprising culturing the cells in the presence of a MUC1* activator.
Claims (12)
1. An antibody or antibody variant that specifically binds to Primary Sequence of the MUC1 Growth Factor Receptor (PSMGFR), the antibody comprising light chain complementarity-determining regions (CDR-L1, CDR-L2, and CDR-L3) and heavy chain complementarity-determining regions (CDR-H1, CDR-H2, and CDR-H3), wherein:
the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 32;
the CDR-L2 comprises the amino acid sequence of SEQ ID NO: 33;
the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 34;
the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 35;
the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 36; and
the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 37.
2. The antibody or antibody variant of claim 1 , which is bivalent.
3. The antibody of claim 1 , which is a monoclonal antibody.
4. The antibody or antibody variant of claim 1 , comprising a kappa light chain variable region comprising the amino acid sequence of SEQ ID NO: 63.
5. The antibody or antibody variant of claim 1 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 64.
6. The antibody or antibody variant of claim 1 , comprising a kappa light chain variable region comprising the amino acid sequence of SEQ ID NO: 63 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 64.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2024
From: BAMDAD, CYNTHIA
To: MINERVA BIOTECHNOLOGIES CORPORATION
Reel/Frame 069480/0223 →
Continuity (7)
Continuation
PCTUS2012029706
· Mar 19, 2012
Provisional Application
61474236
· Apr 11, 2011
Provisional Application
61472516
· Apr 6, 2011
Provisional Application
61453917
· Mar 17, 2011
References Cited (400)
US 3854480A
· Zaffaroni
· 1974
[cited by applicant]
US 4452775A
· Kent
· 1984
[cited by applicant]
US 4675189A
· Kent et al.
· 1987
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5075109A
· Tice et al.
· 1991
[cited by applicant]
US 5133974A
· Paradissis et al.
· 1992
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5407686A
· Patel et al.
· 1995
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5736152A
· Dunn
· 1998
[cited by applicant]
US 5834217A
· Levine et al.
· 1998
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 6087117A
· King et al.
· 2000
[cited by applicant]
US 6617135B1
· Gillies et al.
· 2003
[cited by applicant]
US 7129058B2
· Yamashita
· 2006
[cited by applicant]
US 7700715B2
· Bamdad et al.
· 2010
[cited by applicant]
US 8535944B2
· Bamdad
· 2013
[cited by applicant]
US 8859495B2
· Bamdad
· 2014
[cited by applicant]
US 9334331B2
· Igawa et al.
· 2016
[cited by applicant]
US 20020119568A1
· Berenson et al.
· 2002
[cited by applicant]
US 20020142964A1
· Nissen et al.
· 2002
[cited by applicant]
US 20020156112A1
· Bamdad et al.
· 2002
[cited by applicant]
US 20020169290A1
· Bornaes et al.
· 2002
[cited by applicant]
US 20040002119A1
· Iannone et al.
· 2004
[cited by applicant]
US 20040067585A1
· Wang et al.
· 2004
[cited by applicant]
US 20040192898A1
· Jia et al.
· 2004
[cited by applicant]
US 20050054752A1
· O'Brien et al.
· 2005
[cited by applicant]
US 20050112607A1
· Bamdad et al.
· 2005
[cited by applicant]
US 20060173171A1
· Bamdad
· 2006
[cited by applicant]
US 20060252087A1
· Tang et al.
· 2006
[cited by applicant]
US 20070009918A1
· Glimcher et al.
· 2007
[cited by applicant]
US 20070134713A1
· Cao
· 2007
[cited by applicant]
US 20070264306A1
· Flameng et al.
· 2007
[cited by applicant]
US 20090075926A1
· Bamdad
· 2009
[cited by applicant]
US 20090148535A1
· Bamdad
· 2009
[cited by applicant]
US 20090175867A1
· Thompson et al.
· 2009
[cited by applicant]
US 20090191171A1
· Ma
· 2009
[cited by applicant]
US 20090306035A1
· Peng et al.
· 2009
[cited by applicant]
US 20100003674A1
· Cope et al.
· 2010
[cited by applicant]
US 20100184032A1
· Georgantas et al.
· 2010
[cited by applicant]
US 20100278788A1
· Badoer et al.
· 2010
[cited by applicant]
US 20100285014A1
· Cox, III et al.
· 2010
[cited by applicant]
US 20100311955A1
· Guo et al.
· 2010
[cited by applicant]
US 20110009469A1
· Mendell et al.
· 2011
[cited by applicant]
US 20110014164A1
· Huangfu et al.
· 2011
[cited by applicant]
US 20120115225A1
· Xu
· 2012
[cited by applicant]
US 20120128655A1
· Kim et al.
· 2012
[cited by applicant]
US 20120156246A1
· Bamdad
· 2012
[cited by applicant]
US 20140044696A1
· Bamdad
· 2014
[cited by applicant]
US 20140065113A1
· Bamdad et al.
· 2014
[cited by applicant]
US 20150203823A1
· Bamdad
· 2015
[cited by applicant]
US 20150320840A1
· Bamdad
· 2015
[cited by applicant]
US 20200062812A1
· Bamdad et al.
· 2020
[cited by applicant]
US 20200385485A1
· Bamdad
· 2020
[cited by applicant]
US 20220252604A1
· Bamdad
· 2022
[cited by applicant]
US 20230049461A1
· Bamdad
· 2023
[cited by applicant]
US 20240247229A1
· Bamdad et al.
· 2024
[cited by applicant]
US 20240294590A1
· Bamdad et al.
· 2024
[cited by applicant]
CN 101273060A
· 2008
[cited by applicant]
EP 0239400A2
· 1987
[cited by applicant]
JP 2008543276A
· 2008
[cited by applicant]
JP 2009539413A
· 2009
[cited by applicant]
WO WO8809344A1
· 1988
[cited by applicant]
WO WO8909622A1
· 1989
[cited by applicant]
WO WO9007861A1
· 1990
[cited by applicant]
WO WO9110741A1
· 1991
[cited by applicant]
WO WO9402602A1
· 1994
[cited by applicant]
WO WO9524929A2
· 1995
[cited by applicant]
WO WO9600782A1
· 1996
[cited by applicant]
WO WO9633735A1
· 1996
[cited by applicant]
WO WO9634096A1
· 1996
[cited by applicant]
WO WO0034783A1
· 2000
[cited by applicant]
WO WO0043791A2
· 2000
[cited by applicant]
WO WO0236626A1
· 2002
[cited by applicant]
WO WO02056022A2
· 2002
[cited by applicant]
WO WO02077199A2
· 2002
[cited by applicant]
WO WO03074074A1
· 2003
[cited by applicant]
WO WO03106495A2
· 2003
[cited by applicant]
WO WO03106618A2
· 2003
[cited by applicant]
WO WO2004002259A2
· 2004
[cited by applicant]
WO WO2004022590A2
· 2004
[cited by applicant]
WO WO2005000899A2
· 2005
[cited by applicant]
WO WO2005017148A1
· 2005
[cited by applicant]
WO WO2005019269A2
· 2005
[cited by applicant]
WO WO2005056780A2
· 2005
[cited by applicant]
WO WO2005073383A2
· 2005
[cited by applicant]
WO WO2006105448A2
· 2006
[cited by applicant]
WO WO2007053135A1
· 2007
[cited by applicant]
WO WO2007081740A2
· 2007
[cited by applicant]
WO WO2008035110A1
· 2008
[cited by applicant]
WO WO2008067065A2
· 2008
[cited by applicant]
WO WO2008070171A2
· 2008
[cited by applicant]
WO WO2009042814A1
· 2009
[cited by applicant]
WO WO2009097136A1
· 2009
[cited by applicant]
WO WO2009105570A2
· 2009
[cited by applicant]
WO WO2009123349A1
· 2009
[cited by applicant]
WO WO2009149233A1
· 2009
[cited by applicant]
WO WO2009149956A2
· 2009
[cited by applicant]
WO WO2009152084A2
· 2009
[cited by applicant]
WO WO2009103969A8
· 2010
[cited by applicant]
WO WO2010003118A1
· 2010
[cited by applicant]
WO WO2010017510A1
· 2010
[cited by applicant]
WO WO2010036939A2
· 2010
[cited by applicant]
WO WO2010042562A2
· 2010
[cited by applicant]
WO WO2010042891A2
· 2010
[cited by applicant]
WO WO2010042981A1
· 2010
[cited by applicant]
WO WO2010048567A1
· 2010
[cited by applicant]
WO WO2010056737A2
· 2010
[cited by applicant]
WO WO2010144887A1
· 2010
[cited by applicant]
WO WO2011058558A2
· 2011
[cited by applicant]
WO WO2011103049A2
· 2011
[cited by applicant]
WO WO2011159960A2
· 2011
[cited by applicant]
WO WO2012008302A1
· 2012
[cited by applicant]
WO WO2012051515A2
· 2012
[cited by applicant]
WO WO2012126013A2
· 2012
[cited by applicant]
WO WO2012154759A2
· 2012
[cited by applicant]
WO WO2013059373A2
· 2013
[cited by applicant]
WO WO2014012115A2
· 2014
[cited by applicant]
WO WO2014018679A2
· 2014
[cited by applicant]
Alberts et al. Cell Biology: The Endless Frontier. Mol Biol Cell 21:129-130 (1994).
[cited by applicant]
Al-Hajj et al. Prospective identification of tumorigenic breast cancer cells. PNAS 100(7):3983-3988 (2003).
[cited by applicant]
Al-Hajj et al. Self-renewal and solid tumor stem cells. Oncogene, 23:7274-7282 (2004).
[cited by applicant]
Allsopp et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol 26:1951-1959 (1996).
[cited by applicant]
Altschul, Stephen F. et al. Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs. Nucleic Acids Research 25(17):3389-3402 (1997).
[cited by applicant]
Andrews et al. Comparative Analysis of Cell Surface Antigens Expressed by Cell Lines Derived From Human Germ Cell Tumors. Int J Cancer 66:806-816 (1996).
[cited by applicant]
Aoi et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321:699-702 (2008).
[cited by applicant]
Arndt et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 In metastatic colorectal cancer. BMC Cancer 9(374)1-17 (2009).
[cited by applicant]
Bader et al. The Promise of MicroRNA Replacement Therapy. Cancer Res 70(18):7027-7030 (2010).
[cited by applicant]
Bamdad, Cynthia. The Use of Variable Density Self-Assembled Monolayers to Probe the Structure of a Target Molecule. Biophysical Journal vol. 75,4: pp. 1989-1996 (1998).
[cited by applicant]
Barratt-Boyes et al. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clinical Cancer Research 5:1918-1924 (1999).
[cited by applicant]
Bilitou et al. The NM23 family in development. Mol Cell Biochem 329(1-2):17-33 (2009).
[cited by applicant]
Bonnet et al. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3:730-737 (1997).
[cited by applicant]
Boyer, Laurie A et al. Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells. Cell vol. 122,6: pp. 947-956 (2005).
[cited by applicant]
Briasoulis et al. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 91:909-917 (2001).
[cited by applicant]
Burchell et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res., 47:5476-5482 (1987).
[cited by applicant]
Burdon et al. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Dev Biol 210(1):30-43 (1999).
[cited by applicant]
Byrd et al. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Review 23(1-2):77-99 (2004).
[cited by applicant]
Calin et al. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6(11):857-866, 2006.
[cited by applicant]
Campbell et al. Oct4 targets regulatory nodes to modulate stem cell function. PLoS One 2(6):e553 (2007).
[cited by applicant]
Cao et al. Construction and characterization of an enhanced GFP-tagged anti-BAFF scFv antibody. Appl Microbiol Biotechnol. 79(3):423-31 (2008).
[cited by applicant]
Cao et al. Evolutionary Emergence of microRNAs in Human Embryonic Stem Cells. PLoS One 3(7):e2820.
[cited by applicant]
Chengalvala et al. Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine 15:335-339 (1997).
[cited by applicant]
Ciafre et al. Extensive modulation of a set of MicroRNAs in primary glioblastoma. Biochem Biophys Res Commun. 334(4): 1351-1358 (2005).
[cited by applicant]
Clarke. Isolation and Characterization of Human Mammary Stem Cells. Cell Prolif. 38:375-386 (2005).
[cited by applicant]
Cloosen et al. Mucin-1 is expressed on dendritic cells, both in vitro and in vivo. Int. Immunol. 11:1561-71 (2004).
[cited by applicant]
Corsten et al. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Cytotechncology 9:376-84 (2008).
[cited by applicant]
Dahiyat et al.: De novo protein design: fully automated sequence selection. Science 278(5335):82-87 (1997).
[cited by applicant]
Davis et al. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787 (1996).
[cited by applicant]
Dellatore et al. Mimicking stem cell niches to increase stem cell expansion. Curr Opin Biotechnol 19(5):534-540 (Oct. 1, 2008).
[cited by applicant]
Dexheimer, Thomas S et al. NM23-H2 May Play an Indirect Role in Transcriptional Activation of c-myc Gene Expression But Does Not Cleave The Nuclease Hypersensitive Element III(1). Molecular Cancer Therapeutics vol. 5,5:…
[cited by applicant]
Dubreuil-Lemaire et al. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol 65:337-343 (2…
[cited by applicant]
Edwards, et al. The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS. Journal of Molecular Biology 334(1):103-118 (2003).
[cited by applicant]
Eloit et al. High level of transgene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes. J. Virol. 7:5375-5381 (1997).
[cited by applicant]
Entry for “Pluripotent cell” from Append B: Glossary in 2008 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research. Natl. Res. Counc. and Inst. of Med. Human Embryonic Stem Cell Researc…
[cited by applicant]
Eridani et al. Siem cells: From embryology to cellular therapy? An appraisal of the present state of art. Cytotechnology 44:125-41 (2004).
[cited by applicant]
Fessler et al. MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 118:113-134 (2009).
[cited by applicant]
Foster et al. Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 211(9):1491-1590 (2005).
[cited by applicant]
Fraley et al. New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids. Trends Biochem. Sci. 6:77 (1981).
[cited by applicant]
Fraschini et al. Selective oxidation of primary alcohol groups of 13-cyclodextrin mediated by 2,2,6,6-tetramethylpiperidine-I-oxyl radical (TEMPO). Carbohydrate Research 328(4):585-589 (2000).
[cited by applicant]
Gad et al. Muc1-Derived Glycopeptide Libraries With Improved Mhc Anchors Are Strong Antigens and Prime Mouse T Cells for Proliferative Responses to Lysates of Human Breast Cancer Tissue. Eur. J Immunol 33:1624-1632 (200…
[cited by applicant]
Garzon et al. Targeting microRNA's in cancer: rationale, strategies and challenges. Nature Re-views 9(10):775-89 (2010).
[cited by applicant]
Gendler, Sandra J et al. Molecular Cloning and Expression of Human Tumor-associated Polymorphic Epithelial Mucin. The Journal of Biological Chemistry vol. 265,25: pp. 15286-15293 (1990).
[cited by applicant]
Gervasi et al. nm23 influences proliferation and differentiation of PC12 cells in response to nerve growth factor. Cell Growth Differ 7:1689-1695 (1996).
[cited by applicant]
Gill et al. The novel PARP1-selective inhibitor AZD5305 has reduced haematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models. Poster # 1374 AACR 2021 Annual Apr. 10-19, 2020.
[cited by applicant]
Goel, et al. Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response. Journal of Immunology 173:7358-7367 (2004).
[cited by applicant]
Goldspiel, Barry R. et al. Human Gene Therapy. Clinical Pharmacy 12(7):488-505 (1993).
[cited by applicant]
Gollub et al. Regulation of mucin gene expression in secretory epithelial cells. Biochemical and Biophysical Research Communications 197(2):667-73 (1993) (Abstract).
[cited by applicant]
Graham et al. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65(5):664-70 (1996).
[cited by applicant]
Gregoriadis. Liposomes for drugs and vaccines. Trends in Biotechnology 3:235-241 (1985).
[cited by applicant]
Gunathilake et al. Fabrication of Porous Materials from Natural/Synthetic Biopolymers and Their Composites. Materials 9(991):1-32 (2016).
[cited by applicant]
Guo et al. Klf4 reverts developmentally programmed restriction of ground state pluripotency. Development 136(7):1063-1069 (2009).
[cited by applicant]
Han et al. Tumor initialing cancer stem cells from human breast cancer cell lines. Int J Oncol 34:1449-53 (2009).
[cited by applicant]
Hande et al. Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper. Poster #296 AACR 2021. Apr. 10-15, 2021.
[cited by applicant]
Hanisch. Design of a Muc1-Based Cancer Vaccine. Biochem Soc Trans 33:705-708 (2005).
[cited by applicant]
Hanna, Jacob et al. Human Embryonic Stem Cells With Biological and Epigenetic Characteristics Similar to Those of Mouse ESCs. Proceedings of the National Academy of Sciences of the United States of America vol. 107,20: …
[cited by applicant]
Hikita, Sherry T et al. MUC1 Mediates the Growth of Human Pluripotent Stem Cells. PLoS One vol. 3,10: e3312, pp. 1-13 (2008).
[cited by applicant]
Huang et al. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 65(22):10413-22 (2005).
[cited by applicant]
Huangfu et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26(7):795-797 (2006).
[cited by applicant]
Huangfu et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 26(11):1269-75 (2008).
[cited by applicant]
Illuzzi et al. In vitro cellular profiling of AZD5305, novel PARP1-selective inhibitor and trapper. Poster #1272 AACR2021, Apr. 10-15, 2021.
[cited by applicant]
Irwin et al. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J. Virol. 68:5036-5044 (1994).
[cited by applicant]
Jaenisch, Rudolf et al. Stem Cells, The Molecular Circuitry of Pluripotency and Nuclear Reprogramming. Cell vol. 132,4: pp. 567-582 (2008).
[cited by applicant]
Jarrad et al. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Research, 58(23):5582-5589 (1998).
[cited by applicant]
Jiang et al. Surface-immobilization of adhesion peptides on substrate for ex vivo expansion of cryopreserved cord blood CD34+cells. Biomaterials 27(13):2723-2732 (May 1, 2006).
[cited by applicant]
Johannes et al. Discovery and first structural disclosure of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper. AstraZeneca—AZD5305—a best in class highly selective PARP1 inhibitor. Presentation a…
[cited by applicant]
John et al. Tissue Engineered Bone and Adipose Tissue—An In Vitro Study. Trends Biomater Artif Organs 16:28-33 (2002).
[cited by applicant]
Kaji et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458:771-775 (2009).
[cited by applicant]
Kamata et al. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clin Exp Metastasis 19(8):689-96 (2002).
[cited by applicant]
Kawamura et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 436:1140-4 (2009).
[cited by applicant]
Khan et al. Adjustable Locks and Flexible Keys: Plasticity of Epitope—Paratope Interactions in Germline Antibodies. Journal of Immunology 192:5398-5405 (2014).
[cited by applicant]
Kim, Young-In et al. Point Mutations Affecting the Oligomeric Structure of Nm23-H1 Abrogates its Inhibitory Activity on Colonization and Invasion of Prostate Cancer Cells. Biochemical and Biophysical Research Communicat…
[cited by applicant]
Koller, Beverly H, and Oliver Smithies. Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination. Proceedings of the National Academy of Sciences 86:8932-8935 (1989).
[cited by applicant]
Komarov et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 235:1733-7 (1999).
[cited by applicant]
Kruyt et al. Optimization of Bone Tissue Engineering in Goats. 49th Meeting of the Orthopaedic Research Society, Poster #0929 (Nov. 15, 2007) www.ors.org/Transactions/49/0929.pdf.
[cited by applicant]
Kuchenbauer et al. In-depth characterization of the microRNA trascriptome in a leukemia progression model. Genome Res 18:1787-1797 (2008).
[cited by applicant]
Kufe, et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223-232 (1984).
[cited by applicant]
Kunath et al. FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment. Development 134(16):2895-902 (2007).
[cited by applicant]
Kunkel, Thomas A. Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection. Proceedings of the National Academy of Sciences of the United States of America 82(2):488-492 (1985).
[cited by applicant]
Lakso et al. Embryonic Expression of nm23 during Mouse Organonesis. Cell Growth Differ 3:873-879 (1992).
[cited by applicant]
Lapidot et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648 (1994).
[cited by applicant]
Lascu et al. Quaternary Structure of Nucleoside Diphosphate Kineses. J Bioenerg Biomembr 32(3):227-236 (2000).
[cited by applicant]
Leong et al. Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts. Pathology 35:422-427 (2003).
[cited by applicant]
Ligtnberg, Marjolijn et al. Episialin, a Carcinoma Associated Mucin, is Generated by a Polymorphic Gene Encoding Splice Variants With Alternative Amino Termini. The Journal of Biological Chemistry vol. 265,10: pp. 5573-…
[cited by applicant]
Lin et al. Glial-derived nexin, a differentially expressed gene during neuronal differentiation, transforms HEK cells into neuron-like cells. Int J of Dev Neurosci 23:9-14 (2005).
[cited by applicant]
Lin et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7(2):165-171 (2005).
[cited by applicant]
Lloyd, C. et al. Modelling the Human Immune Response: performance of a 10
[cited by applicant]
Lombardi et al. nm23: Unraveling its Biological Function in Cell Differentiation. J Cell Physiol 182:144-149 (2000).
[cited by applicant]
Lowry, W E et al. Generation of Human Induced Pluripotent Stem Cells From Dermal Fibroblasts. Proceedings of the National Academy of Sciences of the United States of America vol. 105,8: pp. 2883-2888 (2008).
[cited by applicant]
Lu et al. MicroRNA expression profiles classify human cancers. Nature, 435(7043):834-838 (2005).
[cited by applicant]
Luong et al. Expression of Nm23-H1 in AML correlates with white cell count at diagnosis and in vitro acts as a survival factor for primary AMLs cells: evidence of a novel autocrine survival factor in AML. Blood 102(part…
[cited by applicant]
Lyssiotis et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of KIf4. PNAS USA 106:8912-8917 (2009).
[cited by applicant]
MacDonald et al. Site-Directed Mutagenesis of nm23-HI. J Biol Chem 271(41):25107-25116 (1996).
[cited by applicant]
Mahanta, Sanjeev et al. A Minimal Fragment of MUCI Mediates Growth of Cancer Cells. PLoS One vol. 3,4: e2054, pp. 1-12 (2008).
[cited by applicant]
Maherali et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3(3):340-345 (w/Supp Information) (2008).
[cited by applicant]
Maherali, Nimet et al. Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling And Widespread Tissue Contribution. Cell Stem Cell vol. 1,1: pp. 55-70 (2007).
[cited by applicant]
Maimets et al. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene 27:5277-5237 (2008).
[cited by applicant]
Makino et al. Immobilization of leukemia inhibitory factor (LIF) to culture murine embryonic stem cells. J Biosci Bioeng 98(5):374-379 (Jan. 1, 2004).
[cited by applicant]
Masip et al. Reprogramming with defined factors: from induced pluripotency to induced transdifferentiation. Molecular Human Reproduction 16(11):856-868 (2010).
[cited by applicant]
Matsui et al. Characterization of clonogenic multiple myeloma cells. Blood 103:2332-2336 (2004).
[cited by applicant]
Meiri et al. Discovery of microRNAs and other small RNA in solid tumors. Nucleic Acids Res. 38(18):6234-6246 (2010).
[cited by applicant]
Meseguer et al. Human endometrial mucin MUC1 is up-regulated by progesterone and down-regulated in vitro by the human blastocyst. Biol. Reprod. 64(2) 590-601 (2001).
[cited by applicant]
Miyazaki et al. Overexpression of nm23-H2/NDP Kinase B in a Human Oral Squamous Cell Carcinoma Cell Line 36 Results in Reduced Metastasis, Differentiated Phenotype in the Metastatic Site, and Growth Factor-independent P…
[cited by applicant]
Morgan, Richard A, and WF Anderson. Human Gene Therapy. Annual Review of Biochemistry 62:191-217 (1993).
[cited by applicant]
Morin et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 18:610-621 (2008).
[cited by applicant]
Moss. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. PNAS USA 93:11341-11348 (1996).
[cited by applicant]
Moss. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development. Dev. Biol. Stand. 82:55-63 (1994).
[cited by applicant]
Mulligan, Richard C. The Basic Science of Gene Therapy. Science 260(5110):926-932 (1993).
[cited by applicant]
Nakagawa et al., Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotechnology 26:101-106 (2008).
[cited by applicant]
Negroni et al. Neuroblastoma Specific Effects of DR-nrn23 and its Mutant Forms on Differentiation and Apoptosis. Cell Death Differ 7:843-850 (2000).
[cited by applicant]
Neveu et al. MicroRNA Profiling Reveals Two Distinct p53-Related Human Pluripotent Stem Cell States. Cell Stem Cell 7(6):671-81 (2010).
[cited by applicant]
Nichols, Jennifer et al. Naive and Primed Pluripotent States. Cell Stem Cell vol. 4,6: pp. 487-492 (2009).
[cited by applicant]
Okabe-Kado et al., Inhibitory Action of nm23 Proteins on Induction of Erythroid Differentiation of Human Leukemia Cells. Biochimica Biophys Acta 1267:101-106 (1995).
[cited by applicant]
Okabe-Kado et al. Physiological and Pathological Relevance of Extracellular NM23INDP Kinases, J Bioenerg Biomembr 35(1):89-93 (2003).
[cited by applicant]
Okabe-Kado, Junko et al. A New Function of Nrn231NDP Kinase as a Differentiation Inhibitory Factor, Which Does Not Require it's Kinase Activity. FEES Letters vol. 363,3: pp. 311-315 (1995).
[cited by applicant]
Okabe-Kado, Junko et al. Characterization of a Differentiation-Inhibitory Activity from Nondifferentiating Mouse Myeloid Leukemia cells. Cancer Research vol. 45, 10: pp. 4848-4852 (1985).
[cited by applicant]
Okabe-Kado, Junko et al. Identity of a Differentiation Inhibiting Factor for Mouse Myeloid Leukemia Cells With NM23/Nucleoside Diphosphate Kinase. Biochemical and Biophysical Research Communications vol. 182,3: pp. 987-…
[cited by applicant]
Okita et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 322(5903):949-953 (2008).
[cited by applicant]
Okita, keisuke et al. Generation of Germline-competent Induced Pluripotent Stem Cells. Nature vol. 448,7151: pp. 313-317 (2007).
[cited by applicant]
Paoletti, Enzo. Applications of Pox Virus Vectors to Vaccination: An Update. Proceedings of the National Academy of Sciences of the United States of America vol. 93,21: pp. 11349-11353 (1996).
[cited by applicant]
Park, In-Hyun et al. Reprogramming of Human Somatic Cells to Pluripotency with Defined Factors. Nature vol. 451,7175: pp. 141-146 (2008).
[cited by applicant]
PCT/US2006/012092 International Search Report Nov. 13, 2006.
[cited by applicant]
PCT/US2009/060272 International Search Report and Written Opinion dated Oct. 17, 2012.
[cited by applicant]
PCT/US2010/038438 International Search Report and Written Opinion dated Nov. 5, 2010.
[cited by applicant]
PCT/US2011040792 International Search Report and Written Opinion dated Feb. 29, 2012.
[cited by applicant]
PCT/US2012/029706 International Search Report and Written Opinion dated Oct. 1, 2012.
[cited by applicant]
Plunkett et al. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional COB+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. Int J Cancer 109(5)…
[cited by applicant]
Poosarla, et al. Computational de novo design of antibodies binding to a peptide with high affinity. Biotechnology and Bioengineering 114(6):1331-1342 (2017).
[cited by applicant]
Pugachev et al. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 212:587-594 (1995).
[cited by applicant]
Qaraghuli, et al. Antibody-protein binding and conformational changes: identifying allosteric signalling pathways to engineer a better effector response. Nature Scientific Reports 10(1):13969, 1-10 (2020).
[cited by applicant]
Rabia, et al. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochemical engineering journal 137:365-374 (2018).
[cited by applicant]
Raina et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 69(12):5133-5141 (2009).
[cited by applicant]
Rajabi et al. Mucin 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes & Cancer 1(1):82-68 (2010).
[cited by applicant]
Rudikoff et al. Single amino acid substitution altering antigen-binding Specificity. PNAS USA 79:1979-1983 (1982).
[cited by applicant]
Rughetti et al. Regulated expression of MUC1 epithelial antigen in erythropoiesis. Br. J. Haematol 120(2):344-352 (2003).
[cited by applicant]
Sachdeva et al. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 70(1):378-87 (2010).
[cited by applicant]
Sassen et al. MicroRNA-implications for cancer. Virchows Archive 452(1):1-10 (Nov. 27, 2007).
[cited by applicant]
Sato et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 10(1):55-63 (2004).
[cited by applicant]
Sawhney et al., Bioerodible Hydogels Based on Photopolymerized Poly(ethyleneglycol)-co-poly(d-hydroxy acid) Diacrylate Macromers. Macromolecules 26:81-587 (1993).
[cited by applicant]
Schepeler et al. Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer. Cancer Research 68(15):6416-6426 (2008).
[cited by applicant]
Shan et al. Transplant for marrow stem cell on ischemic heart disease. Chinese Journal Clinical Pharmacology and Therapeutics 7(5):473-476 (2002).
[cited by applicant]
Shaw et al. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB 16:869-71 (2002).
[cited by applicant]
Siegfried Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line. J. Cell Biochem. 41:91-95 (1989).
[cited by applicant]
Silva et al. Capturing Pluripotency. Cell 132(4):532-6 (2008).
[cited by applicant]
Silva et al., Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 6(10):e253 (2008).
[cited by applicant]
Singh et al. Identification of a cancer stem cell in human brain tumors. Cancer Res., 63(18):5821-8 (2003).
[cited by applicant]
Smagghe et al. MUCI ligand, NM23-H1, is a novel growth factor that maintains human stem cells in a more naive state. PLoS One 8(3):E58601 (Mar. 2013).
[cited by applicant]
Snoek et al. Protein Kinase C and Phorbol Ester Receptor expression Related to Growth and Differentiation of Nullipotent and Pluripotent Embryonal Carcinoma Cells. Developmental Biology 115(2):282-292 (1986).
[cited by applicant]
Soldner et al. Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors. Cell 136(5):964-977 (2009).
[cited by applicant]
Sommer et al.: Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27(3):543-549 (2009).
[cited by applicant]
Sorscher et al. Microinjection of an NM23 specific antibody inhibits cell division in rat embryo fibroblasts. Biochem Biophy Res Commun 195(1):336-345 (1993).
[cited by applicant]
Spicer et al. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of mini…
[cited by applicant]
Spizzo et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor -[alpha] in human breast cancer cells. Cell Death and Differentiation 17(2):246-254 (Sep. 4, 2009).
[cited by applicant]
Sridharan et al. Role of the murine reprogramming factors in the induction of pluripotency. Cell 136(2):364-377 (2009).
[cited by applicant]
Stadtfeld et al. Induced pluripotent stem cells generated without viral integration. Science 322(5903):945-9 (2008).
[cited by applicant]
Staniszewska et al. The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in in vivo preclinical models. Poster #1270 AACR 2021. Apr. 10-15 and…
[cited by applicant]
Stavridis et al. A discrete period of FGF-induced Erk1/2 signalling is required for vertebrate neural specification. Development 134:2889-2894 (2007).
[cited by applicant]
Stingl, John et al. Epithelial Progenitors in the Normal Human mammary Gland. Journal of Mammary Gland Biology and Neoplasia vol. 10,1: pp. 49-59 (2005).
[cited by applicant]
Strom et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol. 2(9)474-9 (2006).
[cited by applicant]
Subramaniam et al. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 10(5):359-371 (2010).
[cited by applicant]
Takahashi, Kazutoshi et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861-872 (2007).
[cited by applicant]
Takahashi, Kazutoshi et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell vol. 126,4: pp. 663-676 (2006).
[cited by applicant]
Taulli et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J. Clin. Invest. 119(8):2366-2378 (2009).
[cited by applicant]
Thathiah et al. MT1-MMP mediates MUC1 Shedding independent of TACE/ADAM17. Biochem. J. 382:363-373 (2004).
[cited by applicant]
Thathiah et al., Tumor Necrosis Factor alpha Stimulates Muc1 Synthesis and Ectodomain Release in a Human Uterine Epithelial Cell Line. Endocrinology 145(9):4192-4203 (2004).
[cited by applicant]
Thathiah et al., Tumor Necrosis Factor-alpha Converting Enzyme/Adam 17 Mediates Muc1 Shedding. J Biol Chem 278(5):3386-3394 (2003).
[cited by applicant]
ThermoScientific Datasheet entitled Thermo Scientific Nunclon Vita Surface, 2010 [online]. [Retrieved on Sep. 13, 2012]. Retrieved from the internet: < url: >http://www.thermofisher.com.au/Uploads/file/Scientific/Bio-In…
[cited by applicant]
Thomson et al. Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145-1147 (1998).
[cited by applicant]
Tolstoshev, Paul. Gene Therapy, Concepts, Current Trials and Future Directions. Annual Review Pharmacology and Toxicology 32:573-596 (1993).
[cited by applicant]
Townsend et al. Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens. J. Virol. 71:3365-337…
[cited by applicant]
U.S. Appl. No. 11/278,122 Office Action dated Jan. 11, 2010.
[cited by applicant]
U.S. Appl. No. 11/278,122 Office Action dated Jan. 31, 2008.
[cited by applicant]
U.S. Appl. No. 11/278,122 Office Action dated May 3, 2010.
[cited by applicant]
U.S. Appl. No. 11/278,122 Office Action dated Nov. 22, 2013.
[cited by applicant]
U.S. Appl. No. 11/278,122 Office Action dated Oct. 31, 2008.
[cited by applicant]
U.S. Appl. No. 11/278,122 Office Action dated Sep. 13, 2013.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Aug. 5, 2015.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Dec. 2, 2019.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Feb. 9, 2017.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Jan. 24, 2011.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Jun. 6, 2023.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Mar. 11, 2021.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Mar. 8, 2019.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Nov. 18, 2011.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Nov. 22, 2021.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Nov. 28, 2014.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Oct. 12, 2017.
[cited by applicant]
U.S. Appl. No. 12/577,103 Office Action dated Sep. 15, 2022.
[cited by applicant]
U.S. Appl. No. 12/814,420 Office Action dated Nov. 13, 2012.
[cited by applicant]
U.S. Appl. No. 13/162,558 Office Action dated Aug. 18, 2017.
[cited by applicant]
U.S. Appl. No. 13/162,558 Office Action dated Feb. 10, 2015.
[cited by applicant]
U.S. Appl. No. 13/162,558 Office Action dated Jun. 26, 2013.
[cited by applicant]
U.S. Appl. No. 13/162,558 Office Action dated Jun. 8, 2018.
[cited by applicant]
U.S. Appl. No. 13/162,558 Office Action dated Nov. 2, 2015.
[cited by applicant]
U.S. Appl. No. 13/162,558 Office Action dated Nov. 29, 2016.
[cited by applicant]
U.S. Appl. No. 13/966,214 Office Action dated Aug. 12, 2015.
[cited by applicant]
U.S. Appl. No. 13/966,214 Office Action dated Aug. 20, 2020.
[cited by applicant]
U.S. Appl. No. 13/966,214 Office Action dated Jul. 15, 2016.
[cited by applicant]
U.S. Appl. No. 13/966,214 Office Action dated Mar. 7, 2019.
[cited by applicant]
U.S. Appl. No. 13/966,214 Office Action dated May 18, 2018.
[cited by applicant]
U.S. Appl. No. 13/966,214 Office Action dated Nov. 8, 2019.
[cited by applicant]
U.S. Appl. No. 13/966,214 Office Action dated Sep. 21, 2017.
[cited by applicant]
U.S. Appl. No. 14/209,651 Office Action dated Feb. 4, 2016.
[cited by applicant]
U.S. Appl. No. 14/209,651 Office Action dated Jul. 6, 2017.
[cited by applicant]
U.S. Appl. No. 14/209,651 Office Action dated Jul. 8, 2015.
[cited by applicant]
U.S. Appl. No. 14/480,586 Office Action dated Apr. 7, 2016.
[cited by applicant]
U.S. Appl. No. 14/596,051 Office Action dated Aug. 11, 2023.
[cited by applicant]
U.S. Appl. No. 14/604,579 Office Action dated Sep. 13, 2022.
[cited by applicant]
U.S. Appl. No. 16/912,135 Office Action dated Apr. 17, 2023.
[cited by applicant]
U.S. Appl. No. 16/912,135 Office Action dated Jul. 27, 2023.
[cited by applicant]
U.S. Appl. No. 16/921,352 Office Action dated May 5, 2021.
[cited by applicant]
Vacanti et al. Identification and initial characterization of spore-like cells in adult mammals. J Cell Biochem 80:455-60 (2001).
[cited by applicant]
Vassilev et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848 (2004).
[cited by applicant]
Venturelii et al. Overexpression of dr-nrn23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32d013 myeloid cells. PNAS USA 92:7435-7439 (1995).
[cited by applicant]
Villa-Diaz et al. Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nature Biotechnol 28(6):581-583 (2010).
[cited by applicant]
Wagner et al. Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotechnol 14:840-844 (1996).
[cited by applicant]
Wang et al. miR-145 inhibits breast cancer cell growth through RTKN. International Journal of Oncology 34:1461-1466 (May 1, 2009).
[cited by applicant]
Watanabe, Kiichi et al. A Rock Inhibitor Permits Survival of Dissociated Human Embryonic Stem Cells. Nature Biotechnology vol. 25,6: pp. 681-686 (2007).
[cited by applicant]
Wei et al. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 7(2):167-78 (2005).
[cited by applicant]
Wei et al. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res 67(4):1853-1858 (2007).
[cited by applicant]
Wen et al. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem. 278(39):38029-39 (2003).
[cited by applicant]
Wernig, Marius et al. c-Myc is Dispensable for Direct Reprogramming of Mouse Fibroblasts. Cell Stem Cell vol. 2,1: pp. 10-12 (2008).
[cited by applicant]
Wernig, Marius et al. In Vitro Reprogramming of Fibroblasts Into a Pluripotent ES-cell-like State. Nature vol. 448,7151: pp. 318-324 (2007).
[cited by applicant]
Willems et al. Decrease in Nucleoside Diphosphate Kinase (NDPK/nm23) Expression during Hematopoietic Maturation. J Biol Chem 273(22):13663-8 (1998).
[cited by applicant]
Willems et al. Extracellular Nucleoside Diphosphate Kinase NM231NDPK Modulates Normal Hematopoietic Differentiation. Experimental Hematology 30:640-648 (2002).
[cited by applicant]
Woltjen, Knut et al. Piggybac Transposition Reprograms Fibroblasts to Induced Pluripotent Stem Cells. Nature vol. 458,7239: pp. 766-770 (2009).
[cited by applicant]
Wright et al. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother 23(1)2-10 (2000).
[cited by applicant]
Wu et al. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 262(10):4429-4432 (1987).
[cited by applicant]
Wu, George Y, and C H Wu et al. Delivery systems for Gene Therapy. Biotherapy 3(1):87-95 (1991).
[cited by applicant]
Xiang et al. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219:220-227 (1996).
[cited by applicant]
Xu et al. MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells. Cell. 137(4):647-658 (2009).
[cited by applicant]
Yamanaka, Shinya. Strategies and New Developments in the Generation of Patient-specific Pluripotent Stem Cells. Cell Stem Cell vol. 1,1: pp. 39-49 (2007).
[cited by applicant]
Yamashita et al. Forskolin and phorbol ester have opposite effects on the expression of mucin-associated sialyl-LewisAa in pancreatic cancer cells. European Journal of Cancer 36(1):113-120 (2000).
[cited by applicant]
Yu et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920 (2007).
[cited by applicant]
Yu, Junying et al. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. Science vol. 324,5928: pp. 797-801 (2009).
[cited by applicant]
Yunbin et al. Effect of hematopoietic growth factors on short expansion of umbilical cord blood CD34+ cells in vitro. Journal Fujian Medical College 37(2):147-50 (2003).
[cited by applicant]
Zhao et al. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. PNAS USA 92:3009-3013 (1995).
[cited by applicant]
Zhong XY, et al. Evaluation of MUC1 and EGP40 in Bone marrow and Peripheral Blood as a Marker for Occult breast cancer. Archvies of Gynecology and Obstetrics vol. 264,4: pp. 177-181 (2001).
[cited by applicant]
Zhou et al. Expression and purification of single chain anti-HBx antibody in
[cited by applicant]
Zhou, Hongyan et al. Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins. Cell Stem Cell vol. 4,5: pp. 381-384 (2009).
[cited by applicant]
Zijlstra, Maarten et al. Germ-line transmission of a disrupted β2-microglobulin gene produced by homologous recombination in embryonic stem cells. Nature 342:435-438 (1989).
[cited by applicant]
Zotter et al. Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland. Int J Cancer Suppl 3:38-44 (1988).
[cited by applicant]
Zou, Xiaoming et al. P53 Deficiency Increases Transformation by V-Abl and Rescues the Ability of a C-terminally Truncated V-Abl Mutant to Induce Pre-B Lymphoma in Vivo. Molecular Cell Biology vol. 20,2: pp. 628-633 (200…
[cited by applicant]
Agou et al. Chapter 29: In Vivo Protein Cross-Linking. From Protein-Protein Interactions: Methods and Applications 261:427-442 (2004).
[cited by applicant]
Amendola et al. DR-nm23 gene expression in neuroblastoma cells: relationship to integrin expression, adhesion characteristics, and differentiation. J Natl Cancer Inst. 89(17):1300-1310 (1997).
[cited by applicant]
Bakiri et al. Promoter Specificity and Biological Activity of Tethered AP-1 Dimers. Mol Cell Biol 22(13):4952-4964 (2002).
[cited by applicant]
BD ITS+. Screenprint of Becton Dickinson's webpage detailing the composition of ITS+ accessed at https://www.annericanpharnnaceuticalreview.conn/25243-Cell-Culture-Growth-Factors/5821288-ITS-Universal-Cell-Culture-Suppl…
[cited by applicant]
Boissan, Mathieu et al. The Mammalian Nm23/NDPK Family: from Metastasis Control to Cilia Movement. Molecular Cell Biochemistry 329(1-2):51-62 (2009).
[cited by applicant]
Breitenlechner, Christine et al. Protein Kinase A in Complex With Rho-kinase Inhibitors Y-27632, Fasudil, and H-1152p: Structural Basis of Selectivity. Structure 11(12):1595-1607 (2003).
[cited by applicant]
Brugger, Wolfram et al. Expression of MUC-1 Epitopes on Normal Bone Marrow: Implications for the Detection of Micrometastatic Tumor Cells. Journal of Clinical Oncology 17(5):1535-1544 (1999).
[cited by applicant]
Carter, M. G. et al. A Primitive Growth Factor, NME7AB , Is Sufficient to Induce Stable Naïve State Human Pluripotency; Reprogramming in This Novel Growth Factor Confers Superior Differentiation. Stem Cells 34(4):847-85…
[cited by applicant]
Chae et al. Transactivation potential of the C-terminus of human NM23-H1. Febs Letters 423(2):235-238 (Mar. 3, 1998).
[cited by applicant]
Chang et al. A nucleoside diphosphate kinase A (NM23-H1) serine 120—glycine substitution in advanced 5 stage neuroblastoma affects enzyme stability and alters protein-protein interaction. Oncogene 12(3):659-667 (Feb. 19…
[cited by applicant]
Chen et al., A Novel Signaling by Vitamin A/retinol Promotes Self Renewal of Mouse Embryonic Stem Cells by Activating PI3K/Akt Signaling Pathway via Insulin-Like Growth factor-1 Receptor. Stem Cells 28(1):57-63 (2010).
[cited by applicant]
Chen, Guokai et al. Chemically Defined Conditions for Human iPSC Derivation and Culture. Nature Methods 8(5):424-431 (2011).
[cited by applicant]
Database UniProt[online], Accession No. P15531,Nov. 30, 2010 uploaded, [retrieved on Aug. 19, 2021], ,Definition:RecName >https://www.uniprot.org/uniprot/P15531.txt?version=131,Definition:RecName : Full=Nucleoside dipho…
[cited by applicant]
Dearolf et al. Developmental consequences of awdb3, a cell-autonomous lethal mutation of
[cited by applicant]
Cited By (1)